Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC Meeting Abstract


Authors: Jänne, P.; Yu, H.; Johnson, M.; Steuer, C.; Vigliotti, M.; Shipitofsky, N.; Guevara, F. M.; Chen, S.; Yu, C.
Abstract Title: Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC
Meeting Title: IASLC 19th World Conference on Lung Cancer
Keywords: drug resistance; egfr mutation; her3
Journal Title: Journal of Thoracic Oncology
Volume: 13
Issue: 10 Suppl.
Meeting Dates: 2018 Sep 23-26
Meeting Location: Toronto, Canada
ISSN: 1556-0864
Publisher: Elsevier Inc.  
Date Published: 2018-10-01
Start Page: S815
End Page: S816
Language: English
ACCESSION: WOS:000454014503101
DOI: 10.1016/j.jtho.2018.08.1438
PROVIDER: wos
Notes: Meeting Abstract: P2.13-43 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Helena Alexandra Yu
    281 Yu